Request for Covid-19 Impact Assessment of this Report

Pharmaceuticals

Global Choroidal Neovascularization Drug Market Growth 2022-2028

  • LP 4923181
  • 111 Pages
  • March 2022
  • Pharmaceuticals
Download Sample    Get Discount   
 
As the global economy mends, the 2021 growth of Choroidal Neovascularization Drug will have significant change from previous year. According to our (LP Information) latest study, the global Choroidal Neovascularization Drug market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Choroidal Neovascularization Drug market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Choroidal Neovascularization Drug market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Choroidal Neovascularization Drug market, reaching US$ million by the year 2028. As for the Europe Choroidal Neovascularization Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Choroidal Neovascularization Drug players cover Cellphire, Inc., Chrysalis BioTherapeutics, Inc., Cleveland BioLabs, Inc., and Cumberland Pharmaceuticals, Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Choroidal Neovascularization Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

AVMOC-001

BB-3

BBT-007

DG-3

Entolimod

EWA-001

Others

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Clinic

Hospital

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

Cellphire, Inc.

Chrysalis BioTherapeutics, Inc.

Cleveland BioLabs, Inc.

Cumberland Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Inc.

Eli Lilly and Company

GNI Group Ltd.

Humanetics Corporation

INSYS Therapeutics, Inc.

Meabco A/S

Neumedicines Inc.

Onconova Therapeutics, Inc.

PharmaIN Corporation

Pluristem Therapeutics Inc.

ProCertus BioPharm Inc.

RDD Pharma Ltd.

RedHill Biopharma Ltd.

RxBio, Inc.

Soligenix, Inc.

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Choroidal Neovascularization Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Choroidal Neovascularization Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Choroidal Neovascularization Drug by Country/Region, 2017, 2022 & 2028

2.2 Choroidal Neovascularization Drug Segment by Type

2.2.1 AVMOC-001

2.2.2 BB-3

2.2.3 BBT-007

2.2.4 DG-3

2.2.5 Entolimod

2.2.6 EWA-001

2.2.7 Others

2.3 Choroidal Neovascularization Drug Sales by Type

2.3.1 Global Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Choroidal Neovascularization Drug Sale Price by Type (2017-2022)

2.4 Choroidal Neovascularization Drug Segment by Application

2.4.1 Clinic

2.4.2 Hospital

2.4.3 Others

2.5 Choroidal Neovascularization Drug Sales by Application

2.5.1 Global Choroidal Neovascularization Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Choroidal Neovascularization Drug Sale Price by Application (2017-2022)

3 Global Choroidal Neovascularization Drug by Company

3.1 Global Choroidal Neovascularization Drug Breakdown Data by Company

3.1.1 Global Choroidal Neovascularization Drug Annual Sales by Company (2020-2022)

3.1.2 Global Choroidal Neovascularization Drug Sales Market Share by Company (2020-2022)

3.2 Global Choroidal Neovascularization Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Choroidal Neovascularization Drug Revenue by Company (2020-2022)

3.2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Company (2020-2022)

3.3 Global Choroidal Neovascularization Drug Sale Price by Company

3.4 Key Manufacturers Choroidal Neovascularization Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Choroidal Neovascularization Drug Product Location Distribution

3.4.2 Players Choroidal Neovascularization Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Choroidal Neovascularization Drug by Geographic Region

4.1 World Historic Choroidal Neovascularization Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Choroidal Neovascularization Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Choroidal Neovascularization Drug Annual Revenue by Geographic Region

4.2 World Historic Choroidal Neovascularization Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Choroidal Neovascularization Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Choroidal Neovascularization Drug Annual Revenue by Country/Region

4.3 Americas Choroidal Neovascularization Drug Sales Growth

4.4 APAC Choroidal Neovascularization Drug Sales Growth

4.5 Europe Choroidal Neovascularization Drug Sales Growth

4.6 Middle East & Africa Choroidal Neovascularization Drug Sales Growth

5 Americas

5.1 Americas Choroidal Neovascularization Drug Sales by Country

5.1.1 Americas Choroidal Neovascularization Drug Sales by Country (2017-2022)

5.1.2 Americas Choroidal Neovascularization Drug Revenue by Country (2017-2022)

5.2 Americas Choroidal Neovascularization Drug Sales by Type

5.3 Americas Choroidal Neovascularization Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Choroidal Neovascularization Drug Sales by Region

6.1.1 APAC Choroidal Neovascularization Drug Sales by Region (2017-2022)

6.1.2 APAC Choroidal Neovascularization Drug Revenue by Region (2017-2022)

6.2 APAC Choroidal Neovascularization Drug Sales by Type

6.3 APAC Choroidal Neovascularization Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Choroidal Neovascularization Drug by Country

7.1.1 Europe Choroidal Neovascularization Drug Sales by Country (2017-2022)

7.1.2 Europe Choroidal Neovascularization Drug Revenue by Country (2017-2022)

7.2 Europe Choroidal Neovascularization Drug Sales by Type

7.3 Europe Choroidal Neovascularization Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Choroidal Neovascularization Drug by Country

8.1.1 Middle East & Africa Choroidal Neovascularization Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Choroidal Neovascularization Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Choroidal Neovascularization Drug Sales by Type

8.3 Middle East & Africa Choroidal Neovascularization Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Choroidal Neovascularization Drug

10.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug

10.4 Industry Chain Structure of Choroidal Neovascularization Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Choroidal Neovascularization Drug Distributors

11.3 Choroidal Neovascularization Drug Customer

12 World Forecast Review for Choroidal Neovascularization Drug by Geographic Region

12.1 Global Choroidal Neovascularization Drug Market Size Forecast by Region

12.1.1 Global Choroidal Neovascularization Drug Forecast by Region (2023-2028)

12.1.2 Global Choroidal Neovascularization Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Choroidal Neovascularization Drug Forecast by Type

12.7 Global Choroidal Neovascularization Drug Forecast by Application

13 Key Players Analysis

13.1 Cellphire, Inc.

13.1.1 Cellphire, Inc. Company Information

13.1.2 Cellphire, Inc. Choroidal Neovascularization Drug Product Offered

13.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Cellphire, Inc. Main Business Overview

13.1.5 Cellphire, Inc. Latest Developments

13.2 Chrysalis BioTherapeutics, Inc.

13.2.1 Chrysalis BioTherapeutics, Inc. Company Information

13.2.2 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Offered

13.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Chrysalis BioTherapeutics, Inc. Main Business Overview

13.2.5 Chrysalis BioTherapeutics, Inc. Latest Developments

13.3 Cleveland BioLabs, Inc.

13.3.1 Cleveland BioLabs, Inc. Company Information

13.3.2 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Offered

13.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Cleveland BioLabs, Inc. Main Business Overview

13.3.5 Cleveland BioLabs, Inc. Latest Developments

13.4 Cumberland Pharmaceuticals, Inc.

13.4.1 Cumberland Pharmaceuticals, Inc. Company Information

13.4.2 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Offered

13.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Cumberland Pharmaceuticals, Inc. Main Business Overview

13.4.5 Cumberland Pharmaceuticals, Inc. Latest Developments

13.5 Diffusion Pharmaceuticals Inc.

13.5.1 Diffusion Pharmaceuticals Inc. Company Information

13.5.2 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Offered

13.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Diffusion Pharmaceuticals Inc. Main Business Overview

13.5.5 Diffusion Pharmaceuticals Inc. Latest Developments

13.6 Eli Lilly and Company

13.6.1 Eli Lilly and Company Company Information

13.6.2 Eli Lilly and Company Choroidal Neovascularization Drug Product Offered

13.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Eli Lilly and Company Main Business Overview

13.6.5 Eli Lilly and Company Latest Developments

13.7 GNI Group Ltd.

13.7.1 GNI Group Ltd. Company Information

13.7.2 GNI Group Ltd. Choroidal Neovascularization Drug Product Offered

13.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 GNI Group Ltd. Main Business Overview

13.7.5 GNI Group Ltd. Latest Developments

13.8 Humanetics Corporation

13.8.1 Humanetics Corporation Company Information

13.8.2 Humanetics Corporation Choroidal Neovascularization Drug Product Offered

13.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Humanetics Corporation Main Business Overview

13.8.5 Humanetics Corporation Latest Developments

13.9 INSYS Therapeutics, Inc.

13.9.1 INSYS Therapeutics, Inc. Company Information

13.9.2 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Offered

13.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 INSYS Therapeutics, Inc. Main Business Overview

13.9.5 INSYS Therapeutics, Inc. Latest Developments

13.10 Meabco A/S

13.10.1 Meabco A/S Company Information

13.10.2 Meabco A/S Choroidal Neovascularization Drug Product Offered

13.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Meabco A/S Main Business Overview

13.10.5 Meabco A/S Latest Developments

13.11 Neumedicines Inc.

13.11.1 Neumedicines Inc. Company Information

13.11.2 Neumedicines Inc. Choroidal Neovascularization Drug Product Offered

13.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Neumedicines Inc. Main Business Overview

13.11.5 Neumedicines Inc. Latest Developments

13.12 Onconova Therapeutics, Inc.

13.12.1 Onconova Therapeutics, Inc. Company Information

13.12.2 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Offered

13.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Onconova Therapeutics, Inc. Main Business Overview

13.12.5 Onconova Therapeutics, Inc. Latest Developments

13.13 PharmaIN Corporation

13.13.1 PharmaIN Corporation Company Information

13.13.2 PharmaIN Corporation Choroidal Neovascularization Drug Product Offered

13.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 PharmaIN Corporation Main Business Overview

13.13.5 PharmaIN Corporation Latest Developments

13.14 Pluristem Therapeutics Inc.

13.14.1 Pluristem Therapeutics Inc. Company Information

13.14.2 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Offered

13.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Pluristem Therapeutics Inc. Main Business Overview

13.14.5 Pluristem Therapeutics Inc. Latest Developments

13.15 ProCertus BioPharm Inc.

13.15.1 ProCertus BioPharm Inc. Company Information

13.15.2 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Offered

13.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 ProCertus BioPharm Inc. Main Business Overview

13.15.5 ProCertus BioPharm Inc. Latest Developments

13.16 RDD Pharma Ltd.

13.16.1 RDD Pharma Ltd. Company Information

13.16.2 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Offered

13.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 RDD Pharma Ltd. Main Business Overview

13.16.5 RDD Pharma Ltd. Latest Developments

13.17 RedHill Biopharma Ltd.

13.17.1 RedHill Biopharma Ltd. Company Information

13.17.2 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Offered

13.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.17.4 RedHill Biopharma Ltd. Main Business Overview

13.17.5 RedHill Biopharma Ltd. Latest Developments

13.18 RxBio, Inc.

13.18.1 RxBio, Inc. Company Information

13.18.2 RxBio, Inc. Choroidal Neovascularization Drug Product Offered

13.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.18.4 RxBio, Inc. Main Business Overview

13.18.5 RxBio, Inc. Latest Developments

13.19 Soligenix, Inc.

13.19.1 Soligenix, Inc. Company Information

13.19.2 Soligenix, Inc. Choroidal Neovascularization Drug Product Offered

13.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.19.4 Soligenix, Inc. Main Business Overview

13.19.5 Soligenix, Inc. Latest Developments

14 Research Findings and Conclusion

List of Tables

Table 1. Choroidal Neovascularization Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Choroidal Neovascularization Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of AVMOC-001

Table 4. Major Players of BB-3

Table 5. Major Players of BBT-007

Table 6. Major Players of DG-3

Table 7. Major Players of Entolimod

Table 8. Major Players of EWA-001

Table 9. Major Players of Others

Table 10. Global Choroidal Neovascularization Drug Sales by Type (2017-2022) & (K Pcs)

Table 11. Global Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)

Table 12. Global Choroidal Neovascularization Drug Revenue by Type (2017-2022) & ($ million)

Table 13. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2017-2022)

Table 14. Global Choroidal Neovascularization Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 15. Global Choroidal Neovascularization Drug Sales by Application (2017-2022) & (K Pcs)

Table 16. Global Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)

Table 17. Global Choroidal Neovascularization Drug Revenue by Application (2017-2022)

Table 18. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2017-2022)

Table 19. Global Choroidal Neovascularization Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 20. Global Choroidal Neovascularization Drug Sales by Company (2020-2022) & (K Pcs)

Table 21. Global Choroidal Neovascularization Drug Sales Market Share by Company (2020-2022)

Table 22. Global Choroidal Neovascularization Drug Revenue by Company (2020-2022) ($ Millions)

Table 23. Global Choroidal Neovascularization Drug Revenue Market Share by Company (2020-2022)

Table 24. Global Choroidal Neovascularization Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 25. Key Manufacturers Choroidal Neovascularization Drug Producing Area Distribution and Sales Area

Table 26. Players Choroidal Neovascularization Drug Products Offered

Table 27. Choroidal Neovascularization Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 28. New Products and Potential Entrants

Table 29. Mergers & Acquisitions, Expansion

Table 30. Global Choroidal Neovascularization Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 31. Global Choroidal Neovascularization Drug Sales Market Share Geographic Region (2017-2022)

Table 32. Global Choroidal Neovascularization Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 33. Global Choroidal Neovascularization Drug Revenue Market Share by Geographic Region (2017-2022)

Table 34. Global Choroidal Neovascularization Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 35. Global Choroidal Neovascularization Drug Sales Market Share by Country/Region (2017-2022)

Table 36. Global Choroidal Neovascularization Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 37. Global Choroidal Neovascularization Drug Revenue Market Share by Country/Region (2017-2022)

Table 38. Americas Choroidal Neovascularization Drug Sales by Country (2017-2022) & (K Pcs)

Table 39. Americas Choroidal Neovascularization Drug Sales Market Share by Country (2017-2022)

Table 40. Americas Choroidal Neovascularization Drug Revenue by Country (2017-2022) & ($ Millions)

Table 41. Americas Choroidal Neovascularization Drug Revenue Market Share by Country (2017-2022)

Table 42. Americas Choroidal Neovascularization Drug Sales by Type (2017-2022) & (K Pcs)

Table 43. Americas Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)

Table 44. Americas Choroidal Neovascularization Drug Sales by Application (2017-2022) & (K Pcs)

Table 45. Americas Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)

Table 46. APAC Choroidal Neovascularization Drug Sales by Region (2017-2022) & (K Pcs)

Table 47. APAC Choroidal Neovascularization Drug Sales Market Share by Region (2017-2022)

Table 48. APAC Choroidal Neovascularization Drug Revenue by Region (2017-2022) & ($ Millions)

Table 49. APAC Choroidal Neovascularization Drug Revenue Market Share by Region (2017-2022)

Table 50. APAC Choroidal Neovascularization Drug Sales by Type (2017-2022) & (K Pcs)

Table 51. APAC Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)

Table 52. APAC Choroidal Neovascularization Drug Sales by Application (2017-2022) & (K Pcs)

Table 53. APAC Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)

Table 54. Europe Choroidal Neovascularization Drug Sales by Country (2017-2022) & (K Pcs)

Table 55. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2017-2022)

Table 56. Europe Choroidal Neovascularization Drug Revenue by Country (2017-2022) & ($ Millions)

Table 57. Europe Choroidal Neovascularization Drug Revenue Market Share by Country (2017-2022)

Table 58. Europe Choroidal Neovascularization Drug Sales by Type (2017-2022) & (K Pcs)

Table 59. Europe Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)

Table 60. Europe Choroidal Neovascularization Drug Sales by Application (2017-2022) & (K Pcs)

Table 61. Europe Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)

Table 62. Middle East & Africa Choroidal Neovascularization Drug Sales by Country (2017-2022) & (K Pcs)

Table 63. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Country (2017-2022)

Table 64. Middle East & Africa Choroidal Neovascularization Drug Revenue by Country (2017-2022) & ($ Millions)

Table 65. Middle East & Africa Choroidal Neovascularization Drug Revenue Market Share by Country (2017-2022)

Table 66. Middle East & Africa Choroidal Neovascularization Drug Sales by Type (2017-2022) & (K Pcs)

Table 67. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)

Table 68. Middle East & Africa Choroidal Neovascularization Drug Sales by Application (2017-2022) & (K Pcs)

Table 69. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)

Table 70. Key Market Drivers & Growth Opportunities of Choroidal Neovascularization Drug

Table 71. Key Market Challenges & Risks of Choroidal Neovascularization Drug

Table 72. Key Industry Trends of Choroidal Neovascularization Drug

Table 73. Choroidal Neovascularization Drug Raw Material

Table 74. Key Suppliers of Raw Materials

Table 75. Choroidal Neovascularization Drug Distributors List

Table 76. Choroidal Neovascularization Drug Customer List

Table 77. Global Choroidal Neovascularization Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 78. Global Choroidal Neovascularization Drug Sales Market Forecast by Region

Table 79. Global Choroidal Neovascularization Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 80. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Region (2023-2028)

Table 81. Americas Choroidal Neovascularization Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 82. Americas Choroidal Neovascularization Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 83. APAC Choroidal Neovascularization Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 84. APAC Choroidal Neovascularization Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 85. Europe Choroidal Neovascularization Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 86. Europe Choroidal Neovascularization Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 87. Middle East & Africa Choroidal Neovascularization Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 88. Middle East & Africa Choroidal Neovascularization Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 89. Global Choroidal Neovascularization Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 90. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Type (2023-2028)

Table 91. Global Choroidal Neovascularization Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 92. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Type (2023-2028)

Table 93. Global Choroidal Neovascularization Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 94. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Application (2023-2028)

Table 95. Global Choroidal Neovascularization Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 96. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Application (2023-2028)

Table 97. Cellphire, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 98. Cellphire, Inc. Choroidal Neovascularization Drug Product Offered

Table 99. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 100. Cellphire, Inc. Main Business

Table 101. Cellphire, Inc. Latest Developments

Table 102. Chrysalis BioTherapeutics, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 103. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Offered

Table 104. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 105. Chrysalis BioTherapeutics, Inc. Main Business

Table 106. Chrysalis BioTherapeutics, Inc. Latest Developments

Table 107. Cleveland BioLabs, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 108. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Offered

Table 109. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 110. Cleveland BioLabs, Inc. Main Business

Table 111. Cleveland BioLabs, Inc. Latest Developments

Table 112. Cumberland Pharmaceuticals, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 113. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Offered

Table 114. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 115. Cumberland Pharmaceuticals, Inc. Main Business

Table 116. Cumberland Pharmaceuticals, Inc. Latest Developments

Table 117. Diffusion Pharmaceuticals Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 118. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Offered

Table 119. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 120. Diffusion Pharmaceuticals Inc. Main Business

Table 121. Diffusion Pharmaceuticals Inc. Latest Developments

Table 122. Eli Lilly and Company Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 123. Eli Lilly and Company Choroidal Neovascularization Drug Product Offered

Table 124. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 125. Eli Lilly and Company Main Business

Table 126. Eli Lilly and Company Latest Developments

Table 127. GNI Group Ltd. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 128. GNI Group Ltd. Choroidal Neovascularization Drug Product Offered

Table 129. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 130. GNI Group Ltd. Main Business

Table 131. GNI Group Ltd. Latest Developments

Table 132. Humanetics Corporation Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 133. Humanetics Corporation Choroidal Neovascularization Drug Product Offered

Table 134. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 135. Humanetics Corporation Main Business

Table 136. Humanetics Corporation Latest Developments

Table 137. INSYS Therapeutics, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 138. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Offered

Table 139. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 140. INSYS Therapeutics, Inc. Main Business

Table 141. INSYS Therapeutics, Inc. Latest Developments

Table 142. Meabco A/S Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 143. Meabco A/S Choroidal Neovascularization Drug Product Offered

Table 144. Meabco A/S Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 145. Meabco A/S Main Business

Table 146. Meabco A/S Latest Developments

Table 147. Neumedicines Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 148. Neumedicines Inc. Choroidal Neovascularization Drug Product Offered

Table 149. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 150. Neumedicines Inc. Main Business

Table 151. Neumedicines Inc. Latest Developments

Table 152. Onconova Therapeutics, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 153. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Offered

Table 154. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 155. Onconova Therapeutics, Inc. Main Business

Table 156. Onconova Therapeutics, Inc. Latest Developments

Table 157. PharmaIN Corporation Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 158. PharmaIN Corporation Choroidal Neovascularization Drug Product Offered

Table 159. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 160. PharmaIN Corporation Main Business

Table 161. PharmaIN Corporation Latest Developments

Table 162. Pluristem Therapeutics Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 163. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Offered

Table 164. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 165. Pluristem Therapeutics Inc. Main Business

Table 166. Pluristem Therapeutics Inc. Latest Developments

Table 167. ProCertus BioPharm Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 168. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Offered

Table 169. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 170. ProCertus BioPharm Inc. Main Business

Table 171. ProCertus BioPharm Inc. Latest Developments

Table 172. RDD Pharma Ltd. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 173. RDD Pharma Ltd. Choroidal Neovascularization Drug Product Offered

Table 174. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 175. RDD Pharma Ltd. Main Business

Table 176. RDD Pharma Ltd. Latest Developments

Table 177. RedHill Biopharma Ltd. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 178. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Offered

Table 179. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 180. RedHill Biopharma Ltd. Main Business

Table 181. RedHill Biopharma Ltd. Latest Developments

Table 182. RxBio, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 183. RxBio, Inc. Choroidal Neovascularization Drug Product Offered

Table 184. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 185. RxBio, Inc. Main Business

Table 186. RxBio, Inc. Latest Developments

Table 187. Soligenix, Inc. Basic Information, Choroidal Neovascularization Drug Manufacturing Base, Sales Area and Its Competitors

Table 188. Soligenix, Inc. Choroidal Neovascularization Drug Product Offered

Table 189. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 190. Soligenix, Inc. Main Business

Table 191. Soligenix, Inc. Latest Developments

List of Figures

Figure 1. Picture of Choroidal Neovascularization Drug

Figure 2. Choroidal Neovascularization Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Choroidal Neovascularization Drug Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Choroidal Neovascularization Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Choroidal Neovascularization Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of AVMOC-001

Figure 10. Product Picture of BB-3

Figure 11. Product Picture of BBT-007

Figure 12. Product Picture of DG-3

Figure 13. Product Picture of Entolimod

Figure 14. Product Picture of EWA-001

Figure 15. Product Picture of Others

Figure 16. Global Choroidal Neovascularization Drug Sales Market Share by Type in 2021

Figure 17. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2017-2022)

Figure 18. Choroidal Neovascularization Drug Consumed in Clinic

Figure 19. Global Choroidal Neovascularization Drug Market: Clinic (2017-2022) & (K Pcs)

Figure 20. Choroidal Neovascularization Drug Consumed in Hospital

Figure 21. Global Choroidal Neovascularization Drug Market: Hospital (2017-2022) & (K Pcs)

Figure 22. Choroidal Neovascularization Drug Consumed in Others

Figure 23. Global Choroidal Neovascularization Drug Market: Others (2017-2022) & (K Pcs)

Figure 24. Global Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)

Figure 25. Global Choroidal Neovascularization Drug Revenue Market Share by Application in 2021

Figure 26. Choroidal Neovascularization Drug Revenue Market by Company in 2021 ($ Million)

Figure 27. Global Choroidal Neovascularization Drug Revenue Market Share by Company in 2021

Figure 28. Global Choroidal Neovascularization Drug Sales Market Share by Geographic Region (2017-2022)

Figure 29. Global Choroidal Neovascularization Drug Revenue Market Share by Geographic Region in 2021

Figure 30. Global Choroidal Neovascularization Drug Sales Market Share by Region (2017-2022)

Figure 31. Global Choroidal Neovascularization Drug Revenue Market Share by Country/Region in 2021

Figure 32. Americas Choroidal Neovascularization Drug Sales 2017-2022 (K Pcs)

Figure 33. Americas Choroidal Neovascularization Drug Revenue 2017-2022 ($ Millions)

Figure 34. APAC Choroidal Neovascularization Drug Sales 2017-2022 (K Pcs)

Figure 35. APAC Choroidal Neovascularization Drug Revenue 2017-2022 ($ Millions)

Figure 36. Europe Choroidal Neovascularization Drug Sales 2017-2022 (K Pcs)

Figure 37. Europe Choroidal Neovascularization Drug Revenue 2017-2022 ($ Millions)

Figure 38. Middle East & Africa Choroidal Neovascularization Drug Sales 2017-2022 (K Pcs)

Figure 39. Middle East & Africa Choroidal Neovascularization Drug Revenue 2017-2022 ($ Millions)

Figure 40. Americas Choroidal Neovascularization Drug Sales Market Share by Country in 2021

Figure 41. Americas Choroidal Neovascularization Drug Revenue Market Share by Country in 2021

Figure 42. United States Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. Canada Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 44. Mexico Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 45. Brazil Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 46. APAC Choroidal Neovascularization Drug Sales Market Share by Region in 2021

Figure 47. APAC Choroidal Neovascularization Drug Revenue Market Share by Regions in 2021

Figure 48. China Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. Japan Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. South Korea Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. Southeast Asia Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 52. India Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 53. Australia Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 54. Europe Choroidal Neovascularization Drug Sales Market Share by Country in 2021

Figure 55. Europe Choroidal Neovascularization Drug Revenue Market Share by Country in 2021

Figure 56. Germany Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. France Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. UK Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 59. Italy Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 60. Russia Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 61. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Country in 2021

Figure 62. Middle East & Africa Choroidal Neovascularization Drug Revenue Market Share by Country in 2021

Figure 63. Egypt Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. South Africa Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Israel Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 66. Turkey Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 67. GCC Country Choroidal Neovascularization Drug Revenue Growth 2017-2022 ($ Millions)

Figure 68. Manufacturing Cost Structure Analysis of Choroidal Neovascularization Drug in 2021

Figure 69. Manufacturing Process Analysis of Choroidal Neovascularization Drug

Figure 70. Industry Chain Structure of Choroidal Neovascularization Drug

Figure 71. Channels of Distribution

Figure 72. Distributors Profiles

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025

The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...

  • Publish Date: June 24, 2019
  • $1050
Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts

The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...

  • Publish Date: February 18, 2019
  • $1290
Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...

  • Publish Date: December 11, 2018
  • $1390